SU11248 (Sunitinib) does inhibit tumor growth and angiogenesis in an ovarian cancer murine xenograft model

被引：0
|
作者：
Bauerschlag, D. O.
Schem, C.
Tiwari, S.
Meinhold-Heerlein, I.
Mundhenke, C.
Weigel, M.
Egberts, J. H.
Kalthoff, H.
Jonat, W.
Maass, N.
机构：
[1] Univ Hosp Kiel Germany, Kiel, Germany
[2] Univ Hosp, Kiel, Germany
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2008年 / 26卷 / 15期
关键词：
D O I：
10.1200/jco.2008.26.15_suppl.16557
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
16557
引用
收藏
页数：1
相关论文
共 50 条
  • [1] SU11248 inhibit the cancer growth factor and antiangiogenic in Xenograft of ovarian carcinoma mouse model
    Bauerschlag, D. O.
    Schein, C.
    Tiwari, S.
    Meinhold-Heerlein, I
    Jonat, W.
    Maass, N.
    GEBURTSHILFE UND FRAUENHEILKUNDE, 2008, 68 : S61 - S61
  • [2] Inhibition of Tumor growth and Angiogenesis in Ovarian cancer Xenograftmodel by SU 11248 (Sunitinib)
    Bauerschlag, D.
    Schem, C.
    Pecks, U.
    Weigel, M.
    Jonat, W.
    Maass, N.
    Meinhold-Heerlein, I.
    ONKOLOGIE, 2010, 33 : 111 - 111
  • [3] Sunitinib (SU11248) Inhibits Growth of Human Ovarian Cancer in Xenografted Mice
    Bauerschlag, Dirk O.
    Schem, Christian
    Tiwari, Sanjay
    Egberts, Jan H.
    Weigel, Marion T.
    Kalthoff, Holger
    Jonat, Walter
    Maass, Nicolai
    Meinhold-Heerlein, Ivo
    ANTICANCER RESEARCH, 2010, 30 (09) : 3355 - 3360
  • [4] Sunitinib (SUTENT, SU11248) Suppresses Tumor Growth and Induces Apoptosis in Xenograft Models of Human Hepatocellular Carcinoma
    Huynh, H.
    Ngo, V. C.
    Choo, S. P.
    Poon, D.
    Koong, H. N.
    Thng, C. H.
    Toh, H. C.
    Zheng, L.
    Ong, L. C.
    Jin, Y.
    Song, I. C.
    Chang, A. P. C.
    Ong, H. S.
    Chung, A. Y. F.
    Chow, P. K. H.
    Soo, K. C.
    CURRENT CANCER DRUG TARGETS, 2009, 9 (06) : 738 - 747
  • [5] SU11248 (sunitinib) sensitizes pancreatic cancer to the cytotoxic effects of ionizing radiation
    Cuneo, K. C.
    Geng, L.
    Fu, A.
    Orion, D.
    Hallahan, D. E.
    Chakravarthy, A.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2007, 69 (03): : S285 - S285
  • [6] The search for surrogates - physiologic imaging in a breast cancer xenograft model during treatment with SU11248
    Miller, KD
    Miller, M
    Mehrotra, S
    Hutchins, G
    Badve, S
    Murray, LJ
    Sledge, GW
    BREAST CANCER RESEARCH AND TREATMENT, 2003, 82 : S18 - S18
  • [7] SU11248 (sunitinib) sensitizes pancreatic cancer to the cytotoxic effects of ionizing radiation
    Cuneo, Kyle C.
    Geng, Ling
    Fu, Allie
    Orton, Darren
    Hallahan, Dennis E.
    Chakravarthy, Anuradha Bapsi
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2008, 71 (03): : 873 - 879
  • [8] Modulation of biomarkers of angiogenesis during treatment with SU11248 (sunitinib malate) in patients with advanced malignancies
    Deprimo, Samuel E.
    Toner, Guy
    Mitchell, Paul
    De Boer, Richard
    Gibbs, Peter
    Hicks, Rodney
    McArthur, Grant
    Brega, Nicoletta
    McCarthy, Timothy
    Bello, Carlo
    CANCER RESEARCH, 2006, 66 (08)
  • [9] Microhemodynamic consequences of tumor angiogenesis targeting using the tyrosine kinase inhibitor SU11248
    Czabanka, M.
    Erber, R.
    Vinci, M.
    Ullrich, A.
    Vajkoczy, P.
    JOURNAL OF VASCULAR RESEARCH, 2006, 43 (06) : 564 - 564
  • [10] Use of SU11248 to inhibit proangiogenic growth factors in renal cell carcinoma patients
    Kate Matthews
    Nature Clinical Practice Urology, 2006, 3 (4): : 182 - 182
12345